T0	Participants 56 93	postmenopausal breast cancer patients
T1	Participants 432 509	metastatic breast cancer patients with previous exposure to endocrine therapy
T2	Participants 1056 1183	primary tumor tissue from patients who participated in a randomized trial of adjuvant tamoxifen (1-3 years) versus observation.
T3	Participants 2062 2176	CONCLUSIONS Patients whose tumor expresses p-p70S6K, as a marker of downstream PI3K and/or MAPK pathway activation